company background image
TRDA logo

Entrada Therapeutics NasdaqGM:TRDA Voorraadrapport

Laatste prijs

US$17.60

Marktkapitalisatie

US$619.3m

7D

1.3%

1Y

12.5%

Bijgewerkt

04 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

Entrada Therapeutics, Inc.

NasdaqGM:TRDA Voorraadrapport

Marktkapitalisatie: US$619.3m

TRDA Overzicht aandelen

Entrada Therapeutics, Inc., een biotechnologiebedrijf in een klinische fase, ontwikkelt EEV-therapieën (endosomal escape vehicle) voor de behandeling van verschillende neuromusculaire ziekten.

Entrada Therapeutics, Inc. Concurrenten

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Entrada Therapeutics
Historische aandelenkoersen
Huidige aandelenkoersUS$17.60
52 Week HoogtepuntUS$18.17
52 Week LaagUS$10.75
Bèta-0.26
11 maand verandering3.10%
3 maanden verandering19.81%
1 Jaar Verandering12.53%
33 jaar verandering-34.08%
5 jaar veranderingn/a
Verandering sinds IPO-26.51%

Recent nieuws en updates

There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding

Oct 17
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding

Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher

Aug 23
Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher

Entrada Therapeutics: A Complicated Tale

Jun 16

Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

May 29
Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

Recent updates

There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding

Oct 17
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding

Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher

Aug 23
Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher

Entrada Therapeutics: A Complicated Tale

Jun 16

Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

May 29
Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry

These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts

Mar 19
These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts

This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Nov 09
This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year

Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)

May 26
Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts

May 14
Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts

Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?

Mar 08
Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Sep 11
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02

Aug 11

We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

May 28
We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate

We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

Jan 31
We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth

Rendement voor aandeelhouders

TRDAUS BiotechsUS Markt
7D1.3%-0.7%-1.6%
1Y12.5%19.8%30.8%

Rendement versus industrie: TRDA underperformed the US Biotechs industry which returned 19.8% over the past year.

Rendement versus markt: TRDA underperformed the US Market which returned 30.8% over the past year.

Prijsvolatiliteit

Is TRDA's price volatile compared to industry and market?
TRDA volatility
TRDA Average Weekly Movement8.0%
Biotechs Industry Average Movement9.6%
Market Average Movement6.0%
10% most volatile stocks in US Market14.9%
10% least volatile stocks in US Market2.9%

Stabiele aandelenkoers: TRDA has not had significant price volatility in the past 3 months compared to the US market.

Volatiliteit in de loop van de tijd: TRDA's weekly volatility (8%) has been stable over the past year.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
2016168Dipal Doshiwww.entradatx.com

Entrada Therapeutics, Inc., een biotechnologiebedrijf in een klinische fase, ontwikkelt EEV-therapieën (endosomal escape vehicle) voor de behandeling van verschillende neuromusculaire ziekten. Het EEV-platform ontwikkelt een portfolio van oligonucleotide-, antilichaam- en enzym-gebaseerde programma's. Tot de therapeutische kandidaten behoren ENTR-601-44, dat zich in Fase I van de klinische studie bevindt voor de behandeling van Duchenne spierdystrofie, en ENTR-701, dat zich in Fase 1/2 van de klinische studie bevindt voor de behandeling van myotone dystrofie type 1.

Entrada Therapeutics, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Entrada Therapeutics zich tot de beurswaarde?
TRDA fundamentele statistieken
MarktkapitalisatieUS$619.29m
Inkomsten(TTM)US$104.44m
Inkomsten(TTM)US$239.40m

5.9x

Koers/Winstverhouding

2.6x

P/S-verhouding

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
TRDA resultatenrekening (TTM)
InkomstenUS$239.40m
Kosten van inkomstenUS$111.13m
BrutowinstUS$128.27m
Overige uitgavenUS$23.83m
InkomstenUS$104.44m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)2.97
Brutomarge53.58%
Nettowinstmarge43.63%
Schuld/Eigen Vermogen Verhouding0%

Hoe presteerde TRDA op de lange termijn?

Bekijk historische prestaties en vergelijking